All In Biotech

NDA 213411 · Seagen

Tukysa

Tucatinib · Oral · Kinase Inhibitor

NovelBreakthrough therapyAccelerated approvalPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Oct 7, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2020

Apr 17, 2020

Approved uses

3

Original approval plus efficacy supplements

Registered trials

64

6 Phase 3, 18 recruiting

FAERS reports

7,107

4,642 serious, 729 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: HEPATOTOXICITY • TUKYSA can cause severe and fatal hepatotoxicity, particularly after rechallenge [see Warnings and Precautions (5.1) ] . • Obtain liver function tests before initiation and during treatment with TUKYSA. Withhold, reduce dose, or permanently discontinue TUKYSA as recommended based on severity of hepatotoxicity [see Dosage and Administration (2.3) and Warnings and Precautions (5.1) ] . WARNING: HEPATOTOXICITY See full prescribing information for complete boxed warning. • TUKYSA can cause severe and fatal hepatotoxicity, particularly after rechallenge. ( 5.1 ) • Obtain liver function tests before initiation and during treatment with TUKYSA. Withhold, reduce dose, or permanently discontinue based on severity. ( 2.3 , 5.1 )

What it is approved for

From the label in effect Oct 14, 2026.

TUKYSA is a kinase inhibitor indicated: • in combination with trastuzumab and pertuzumab for the maintenance treatment of adult patients with unresectable locally advanced or metastatic HER2-positive breast cancer following induction treatment. ( 1.1 ) • in combination with trastuzumab and capecitabine for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. ( 1.1 ) • in combination with trastuzumab for the treatment of adult patients with RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. ( 1.2 ) This indication is approved under accelerated approval based on tumor response rate and durability of response [see Clinical Studies (14.2) ]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. 1.1 Unresectable or Metastatic Breast Cancer Maintenance Treatment of HER2-Positive Breast Cancer TUKYSA is indicated in combination with trastuzumab and pertuzumab for the maintenance treatment of adult patients with unresectable locally advanced or metastatic HER2-positive breast cancer following induction treatment. HER2-Positive Breast Cancer TUKYSA is indicated in combination with trastuzumab and capecitabine for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. 1.2 Unresectable or Metastatic Colorectal Cancer TUKYSA is...

Mechanism: Tucatinib is a tyrosine kinase inhibitor of HER2. In vitro , tucatinib inhibits phosphorylation of HER2 and HER3, resulting in inhibition of downstream MAPK and AKT signaling and cell proliferation, and showed anti-tumor activity in HER2 expressing tumor cells. In vivo , tucatinib inhibited the growth of HER2 expressing tumors. The combination of tucatinib and trastuzumab showed increased anti-tumor activity in vitro and in vivo compared to either drug alone.

Therapeutic areas: Oncology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Oct 7, 2026 Supplement 10 · Efficacy OrphanLetterLabelMedication Guide
  • Jan 19, 2023 Supplement 4 · Efficacy · priority review Breakthrough therapyOrphanLabelLetter
  • Apr 17, 2020 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyAccelerated approvalOrphanLabelLetterReview
2 products under this application
  • TUKYSA · TUCATINIB 50MG · TABLET, ORAL · Prescription
  • TUKYSA · TUCATINIB 150MG · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Tucatinib" as an intervention, any sponsor and status, largest first.

All 64 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • diarrhoea1,803
  • fatigue980
  • nausea941
  • vomiting533
  • off label use481
  • death472
  • malignant neoplasm progression455
  • palmar-plantar erythrodysaesthesia syndrome418
  • product dose omission issue377
  • asthenia371
  • decreased appetite323
  • disease progression306

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20171
20183
20199
2020797
20211,356
2022974
2023931
20241,684
2025765
2026587

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Tukysa (Tucatinib)

2024 spending

$139M

Beneficiaries

1,182

6,463 claims

Per beneficiary

$117,897

$196.59 per unit

View as table
YearSpending
2020$30,675,582
2021$81,591,015
2022$91,179,471
2023$102,384,647
2024$139,353,830

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 36 on PubMed

Sponsor: Pfizer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.